Press Releases

Press Releases

Date Title
05/01/18 Vaxart Appoints Dr. David Taylor as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 1, 2018-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of David Taylor , M.D., as Chief Medical Officer. Dr.

04/20/18 Vaxart Announces $5 Million Inavir® Revenue Milestone

2017 Net Sales of Inavir ® in Japan Exceeded ¥20 Billion, Triggering USD $5 Million Milestone Payment SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 20, 2018-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than

04/19/18 Vaxart Appoints Brant Biehn as Senior Vice President, Commercial Operations

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 19, 2018-- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of Brant Biehn as Senior Vice President,

04/16/18 Vaxart to Present at Two Upcoming Medical Meetings

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 16, 2018-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that new preclinical data on its intranasal Chikungunya

04/02/18 Vaxart Announces Oral Presentation of Clinical Data from Oral Influenza Vaccine Program at the World Vaccine Congress
SOUTH SAN FRANCISCO, Calif., April 2, 2018 — Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that the complete clinical dataset from the Phase 2 Challenge Study of its H1
03/21/18 Vaxart to Present at the 17th Annual Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that Wouter Latour , M.D., president and chief executive officer of Vaxart , will
03/07/18 Vaxart Expands Intellectual Property Portfolio With U.S. Patent Allowance
Issued Claims Cover High Yield Production Process of Phase 2 Antiviral SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Vaxart, Inc. (NASDAQ: VXRT) a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that the
03/02/18 Vaxart to Present Clinical Data From Oral Norovirus Vaccine Program at International Congress on Infectious Diseases
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will present clinical data from two Phase 1 studies of its
02/14/18 Vaxart, Inc. Closes Merger with Aviragen Therapeutics, Inc.
Vaxart, Inc. Closes Merger with Aviragen Therapeutics, Inc. Combined Company Renamed Vaxart, Inc. and Will Begin Trading Under New Symbol NASDAQ: VXRT SOUTH SAN FRANCISCO, CA and ATLANTA, Feb. 13, 2018 — Vaxart, Inc. (NASDAQ: VXRT) today announced the completion of its merger with Aviragen
02/09/18 Aviragen Adjourns Special Meeting of Stockholders to Allow Stockholders to Consider Improved Merger Deal Terms
CAS Group Supports Improved Deal Company Currently has Sufficient Votes to Approve Merger ATLANTA , Feb. 09, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced that the reconvened Special Meeting of Stockholders has been further adjourned to 10:00 AM, EST on February